In cancers such as osteosarcoma, hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC), or breast cancer, SATB2 expression levels have been observed to be higher than in normal tissues and associated with a poor prognosis. This evidence concerns the gene SATB2 and hepatocellular carcinoma.